Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

德银:首予石药集团(01093)“买入”评级 目标价11.8港元
Deutsche Bank: the target price for CSPC Pharmaceutical's (01093) "buy" rating is HK $11.80.

Zhitong Finance ·  {{timeTz}}

智通财经APP获悉,德银发布研究报告称,首予石药集团(01093)“买入”评级,目标价11.8港元。作为中国领先的制药企业,专注于开发、制造和销售创新药、仿制药和原料药。公司大部分的现有旗舰产品如恩必普(NBP)、玄宁和多美素,占去年总收入逾50%,是推出超过十年的药物。

Zhitong Financial APP learned that Deutsche Bank released a research report saying it first gave CSPC Pharmaceutical a "buy" rating of 01093, with a target price of HK $11.80. As a leading pharmaceutical company in China, it focuses on developing, manufacturing and selling innovative drugs, generics and APIs. Most of the company's existing flagship products, such as NBP, Xuanning and Domesu, accounted for more than 50% of total revenue last year and are drugs that have been launched for more than a decade.

该行预计,新产品可能将成为公司新的股价催化剂,其中如多恩达(DUOENDA)、伊立替康脂质体注射液(Irinotecan liposome)及mRNA疫苗可能填补旧有产品的不足。另认为随着新产品的潜在发行及顺利上市,相信市场将对公司价值重估。

The bank expects that new products may become new catalysts for the company's share price, such as DUOENDA, irinotecan liposome injection (Irinotecan liposome) and mRNA vaccine may make up for the shortcomings of old products. It is also believed that with the potential release and smooth listing of new products, it is believed that the market will revalue the company.

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top